KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Assets (2016 - 2025)

Nektar Therapeutics has reported Assets over the past 16 years, most recently at $280.4 million for Q4 2025.

  • Quarterly results put Assets at $280.4 million for Q4 2025, down 7.72% from a year ago — trailing twelve months through Dec 2025 was $280.4 million (down 7.72% YoY), and the annual figure for FY2025 was $280.4 million, down 7.72%.
  • Assets for Q4 2025 was $280.4 million at Nektar Therapeutics, down from $301.3 million in the prior quarter.
  • Over the last five years, Assets for NKTR hit a ceiling of $1.5 billion in Q1 2021 and a floor of $207.5 million in Q2 2025.
  • Median Assets over the past 5 years was $468.3 million (2023), compared with a mean of $644.7 million.
  • Biggest five-year swings in Assets: crashed 45.15% in 2023 and later decreased 2.15% in 2025.
  • Nektar Therapeutics' Assets stood at $1.1 billion in 2021, then crashed by 36.39% to $710.6 million in 2022, then plummeted by 43.99% to $398.0 million in 2023, then fell by 23.66% to $303.8 million in 2024, then fell by 7.72% to $280.4 million in 2025.
  • The last three reported values for Assets were $280.4 million (Q4 2025), $301.3 million (Q3 2025), and $207.5 million (Q2 2025) per Business Quant data.